Preventive PCI versus only optimal medical therapy for vulnerable plaques
Marc Bonaca, MD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Michael Koren, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Michael Gibson, MD
Sharing insights after study results with icosapent ethyl
Prof. Kausik Ray, MBChB, MD, MPhil
P. Gabriel Steg, MD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.